Compound knowledge base
15 Schedule I and adjacent compounds. Each has real PubMed-cited receptor Ki values, metabolic pathways, drug interactions, toxicology, and FDA status. Queryable by target, potency, or class.
15 Schedule I compounds with PubMed-cited pharmacology. 29 PhD-trained AI expert agents composited from real literature and federal regulation. A DEA Schedule I application drafted in two weeks, not three months.
Built by Michael Crowe — founder of Southwest Mushrooms, author of The Mushroom Grower, principal architect of CriOS Nova and the Crowe Logic AI platform.
A working commercial stack on top of CriOS Nova — Crowe Logic's chemoinformatics engine — and a 194-agent architecture specialized for psychedelic tryptamines, phenethylamines, ergolines, and related scaffolds.
15 Schedule I and adjacent compounds. Each has real PubMed-cited receptor Ki values, metabolic pathways, drug interactions, toxicology, and FDA status. Queryable by target, potency, or class.
24 Molecular Design specialists + 3 Psychedelic Specialists + 2 Core. Each is an AI composite persona grounded in real literature. The reasoning is PhD-grade; the disclosure is honest.
6 Psilocybe species and 6 commercial P. cubensis strains with peer-reviewed alkaloid profiles. Match a target profile to ranked cultivar × strain candidates with predicted dry-weight %.
No signup, no install. Everything below runs on real data from this
platform. The compound browser reads the same JSON records the CLI does.
The cultivar matcher uses the same scoring algorithm
lfpsy cultivar-match runs server-side. The agent reveal
streams previously-generated output from Dr. Nakamura and
Dr. Mullen.
Three revenue surfaces. Each one buys down a specific class of regulatory or scientific friction.
$2,500/month
For preclinical discovery teams, academic labs.
$25,000/application
[LEGAL REVIEW] markers flag every ambiguityFor new Schedule I applicants. Saves ~$15K + 4 weeks vs counsel-only drafting.
$50,000/engagement
For research facilities scaling for clinical supply.
Tier 2 (Q3 2026): CriOS Nova Psy API — $5K/mo per seat. Tier 3 (2027): IND-support and DEA-registered compound characterization.
Founder & CEO, Crowe Logic, Inc. · Chief Mycologist
Twenty-plus years of applied mycology. Commercial operator, published author, and principal architect of the Crowe Logic AI platform — now powering Crowe Psychedelics.
synapse-lang and
synapse-qubit-flow, scientific-computing DSLs for
quantum chemistry and drug-discovery workflows.
"I build the operator's tools. The platform in front of you is what happens when twenty years of mycology meet twenty years of systems engineering."
No signup. Real artifacts generated by this platform.
SMILES proposals, crystal-structure-guided rationale (PDB 6WHA/6WGT), predicted Ki with interpolation basis, ADMET concerns, freedom-to-operate commentary. Grounded in PMIDs 27816818, 32699011, 28129538.
Agent reportResearcher vs analytical-lab choice, 21 CFR 1301 sections,
realistic 8–16 week timeline, top three rejection risks with
mitigations, IND scope, state-level AZ considerations.
10 CFR citations, 6 [LEGAL REVIEW] markers.
Cover letter, research protocol summary, security plan (21 CFR 1301.71–76), three SOPs, facility diagram template, and DEA Form 225 field map. Every file watermarked DRAFT — Legal review required. Generated from a single YAML intake.
30-minute screen-share of the CLI running on your compound of interest. Leave with a pre-populated reg-pack intake YAML and a decision on fit.